Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: A randomized open-label study

Climacteric

Volumn 9, Issue 5, 2006, Pages 368-379

  Samsioe, G ^a   Boschitsch, E ^b   Concin, H ^c   De Geyter, C ^d   Ehrenborg, A ^e   Heikkinen, J ^f   Hobson, R ^g   Arguinzoniz, M ^g   Ibarra De Palacios, P ^g   Scheurer, C ^g   Schmidt, G ^g  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Ambulatorium Klimax   (Austria)

^c Landeskrankenhaus Bregenz   (Austria)

^d UNIVERSITY WOMEN S HOSPITAL   (Switzerland)

^e Specialistläkarna   (Sweden)

^f Osteoporoosiklinikka   (Finland)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Endometrial safety; Estradiol; Norethisterone; Transdermal patch

Indexed keywords

ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; HORMONE DERIVATIVE; PROGESTERONE;

ABDOMINAL PAIN; ADULT; AGED; AMENORRHEA; ARTHRALGIA; ARTICLE; BACKACHE; BREAST TENDERNESS; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ERYTHEMA; FEMALE; HEADACHE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INFLUENZA; LIMB PAIN; LYMPHOMA; METRORRHAGIA; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SKIN IRRITATION; SPOTTING; THROMBOSIS; UTERUS BLEEDING; UTERUS MYOMA; VAGINA BLEEDING; WEIGHT GAIN;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; AGED; DRUG THERAPY, COMBINATION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; PROGESTERONE CONGENERS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 33749026066     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130600953661     Document Type: Article

References (41)

1. Whitehead MI, Fraser D. The effects of estrogens and progestogens on the endometrium. Modern approach to treatment. Obstet Gynecol Clin North Am 1987;14:299-320
2. Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995;86:306-16
3. The Writing Group for the PEPI trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370-5
4. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-7
5. Heikkinen J, Vaheri R, Timonen U. Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomized comparison of low and standard doses. J Br Menopause Soc 2004;10:95-102
6. Wells M, Sturdee DW, Barlow DH, et al. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study. BMJ 2002;325:239
7. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003;290:1739-48
8. Hill DA, Weiss NS, Beresford SA, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000;183:1456-61
9. Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985;152:1099-1106
10. Cedars MI, Judd HL. Non-oral routes of estrogen administration. Obstet Gynecol Clin North Am 1987;14:269-98
11. Cust MP, Gangar KF, Whitehead MI. Administration of steroids by skin patches. Res Reprod 1989;21:1-2
12. Stumpf PG. Pharmacokinetics of estrogen. Obstet Gynecol 1990;75:9-14S
13. Shakir YA, Samsioe G, Nerbrand C, Lidfeldt J. Combined hormone therapy in postmenopausal women with features of metabolic syndrome. Results from a population-based study of Swedish women: Women's Health in the Lund Area study. Menopause 2004;11:549-55
14. Van Erpecum KJ, Van Berge Henegouwen GP, Verschoor L, Stoelwinder B, Willekens FL. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 1991;100:482-8
15. Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract, 4th edn. New York: Springer Verlag, 1994:1-1280
16. Dallenbach-Hellweg G, Poulsen H. Atlas of Endometrial Histopathology, 2nd edn. Berlin: Springer, 1996
17. Kurman RJ, Solomon D. The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses. New York: Springer Verlag, 1994
18. Committee for Proprietary Medical Products (CPMP) Guideline. Points to consider on Hormone Replacement Therapy. November 19, 1997
19. Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. May 1, 2006
20. Munstedt K, Grant P, Woenckhaus J, Roth G, Tinneberg HR. Cancer of the endometrium: current aspects of diagnostics and treatment. World J Surg Oncol 2004;2:24
21. North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003;10:113-32
22. Lethaby A, Suckling J, Barlow D, Farquhar CM, Jepson RG, Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004;3:CD000402
23. Korhonen MO, Symons JP, Hyde BM, Rowan JP, Wilborn WH. Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol 1997;176:377-80
24. Archer DF, Furst K, Tipping D, Dain MP, Vandepol C. A randomized comparison of continuous combined transdermal delivery of estradiol- norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999;94:498-503
25. Shulman LP, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause 2002;9:195-207
26. Mattsson LÅ, Bohnet HG, Gredmark T, Torhorst J, Hornig F, Huls G. Continuous, combined hormone replacement: randomized comparison of transdermal and oral preparations. Obstet Gynecol 1999;94:61-5
27. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994;83:686-92
28. Shau WY, Hsieh CC, Hsieh TT, Hung TH, Huang KE. Factors associated with endometrial bleeding in continuous hormone replacement therapy. Menopause 2002;9:188-94
29. Marsden J. Hormone-replacement therapy and breast cancer. Lancet Oncol 2002;3:303-11
30. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27
31. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243-53
32. Colditz GA. Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res 2005;11:909-17s
33. American Cancer Society. Cancer facts and figures 2004. Atlanta, GA, USA: American Cancer Society Inc, 2004:14 (www.cancer.org/downloads/STT/ CAFF_finalPWSecured.pdf)
34. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59
35. Crandall C. Low-dose estrogen therapy for menopausal women: a review of efficacy and safety. J Womens Health (Larchmt) 2003;12:723-47
36. Harvey J, Scheurer C, Kawakami FT, Quebe-Fehling E, Ibarra de Palacios P, Ragavan VV. Hormone replacement therapy and breast density changes. Climacteric 2005;8:185-92
37. Erberich LC, Alcantara VM, Picheth G, Scartezini M. Hormone replacement therapy in postmenopausal women and its effects on plasma lipid levels. Clin Chem Lab Med 2002;40:446-51
38. Munk-Jensen N, Ulrich LG, Obel EB, Nielsen SP, Edwards D, Meinertz H. Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: effect of plasma lipoproteins in a two-year placebo-controlled trial. Am J Obstet Gynecol 1994;171:132-8
39. Brynhildsen J, Hammar M. Lipids and clotting factors during low dose transdermal estradiol/norethisterone use. Maturitas 2005;50:344-52
40. Castelo-Branco C, Casals E, Sanllehy C, Duran M, Fortuny A, Vanrell JA. Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate. J Reprod Med 1996;41:833-8
41. Bhathena R, Anklesaria BS, Ganatra AM, Pinto R. The influence of medroxyprogesterone acetate on the effects of transdermal oestradiol replacement therapy on plasma lipids. J Obstet Gynaecol 1998;18:141-5